good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics, and devices according to their best knowledge and judgment. 1 If physicians use a product for an indication not in the approved labeling, they have the responsibility to be well informed about the product, and to base its use on firm scientific rationale and sound medical evidence. 1 The term "off-label" use refers to use of a drug that is not included in the package insert (approved labeling) for that drug. 2 The application of drugs in accordance with the marketing authorization issued by the regulatory authority is considered on-label use, while off-label drug use frequently occurs in medical practice. 3 Medical specialists frequently prescribe an off-label drug in pediatrics, neonatology, geriatrics, psychiatry, and oncology. 3 Off-label medication use accounts for an estimated 50% of medication prescribing. 4 The purpose of off-label use is to benefit an individual patient. It is important to note that the term off-label does not imply an improper, illegal, contraindicated, or investigational use. 2 Although this practice is appropriate and defensible when based on sound scientific evidence, safety concerns resulting from unexpected adverse clinical effects have been documented. 4, 5 Questions about quality of care become particularly challenging, and the boundary of research versus clinical practice becomes blurred, when there is a substantial theoretical rationale for off-label medication use based on its mechanism of action, but only little or sparse empirical clinical data support, only anecdotal or methodologically flawed evidence, or substantial concerns regarding the cost-effectiveness of the medication. 5 Ansani and colleagues used the term "innovative offlabel drug use" to describe (a) prescribing that has a reasonable rationale for use, but (b) has insufficient evidence to thoroughly allay concerns about its safety, efficacy, and cost-effectiveness for the innovative use, yet (c) is not considered clinical research. In 2006, Ansani and colleagues performed a survey to determine the number of academic medical centers that had identified innovative off-label drug use as a problem, and surprisingly, found only limited structured review processes for innovative off-label medication uses in existence; yet, it was a common problem throughout the nation. 5 The FDA is the federal government agency charged with oversight responsibility for the manufacturing, labeling, advertisement, and safety of therapeutic drugs. The Food, Drug, and Cosmetic Act requires that "substantial evidence," resulting from "adequate and wellcontrolled investigations" demonstrating that a new drug "will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the proposed labeling," be submitted to and reviewed and approved by the FDA before a drug is marketed in interstate commerce. 2 Historically, for the past half century, physicians and clinical researchers have remained confident that randomized controlled trials (RCTs) provide the most rigorous test of preventive, diagnostic, and therapeutic interventions. 6 They are ubiquitously referred to as the "gold standard" of empirical biomedical investigation. However, this status has long been contested, ever more so now with the emergence of "big data," randomized registry trials, and other modes of knowledge production in medicine. 6 RCTs are the most reliable methods to determine the effects of treatment. They must be internally valid, and to be clinically useful the result must also be relevant to a definable group of patients in a particular clinical setting; this is generally termed external validity, applicability, or generalizability. 7 There is concern among clinicians that external validity is often poor, particularly for some pharmaceutical industry trials, a perception that has led to underuse of treatments that are effective. 7 Yet researchers, funding agencies, ethics committees, the pharmaceutical industry, medical journals, and governmental regulators alike all neglect external validity, leaving clinicians to make judgments. However, reporting of the determinants of external validity in trial publications and systematic reviews is usually inadequate. 7 Issues that may potentially affect external validity include the setting of the trial (eg, country, health care system, participating patients and clinicians), patient selection (eg, inclusion/exclusion criteria, enrichment strategies), patient characteristics (eg, severity of diseases, comorbidity, stage of natural history of their disease), and differences between the trial protocol and routine practice, outcome measures and follow-up, and adverse effects of treatment, among others. 7 In addition, the rise of personalized medicine might make it more difficult to defend gold standards (RCTs) in diagnostic and therapeutic practice. Personalized medicine refocuses clinical attention away from the "typical" patients analyzed by RCTs and onto the idiosyncrasies, genetic or otherwise, of individual patients. 6 In a recent article titled "Personalized Medicine: Time for One-person Trials," Nicholas J. Schork opined, Every day, millions of people are taking medications that will not help them. The top 10 highest-grossing drugs in the United States help between 1 in 25 and 1 in 4 of the people who take them. For some drugs, such as statins, routinely used to lower cholesterol, as few as 1 in 50 may benefit. 8 Schork further opined, Classical clinical trials harvest a handful of measurements from thousands of people. Precision medicine requires different ways of testing interventions. . . . Studies that focus on a single person, known as N-of-1 trials, will be a crucial part of the mix. . . . Aggregated results of many N-of-1 trials, all carried out in the same way, will offer information about how to better treat subsets of the population or even the population at large. 8 Nevertheless, knowledge of the benefits and risks of prescription drugs is based mainly on published reports of clinical trials, yet the medical literature may present an incomplete and potentially biased sample of clinical trials. 9 Trials with positive results generally are published more frequently than studies that conclude that a new drug poses greater risks or is no more effective than standard therapy or a placebo. Furthermore, some articles may distort trial findings by omitting important data or by modifying prespecified outcome measures. Lack of access to detailed information about clinical trials can undermine the integrity of medical knowledge. 10 In this regard, on-label drug use does not automatically guarantee safe, effective, or even applicable treatment for an individual patient encountered in clinical practice; meanwhile, the term "off-label" does not imply an improper, illegal, contraindicated, or investigational use. Labeling is not intended to preclude the practitioner from using his or her best medical judgment in the interest of patients or to impose liability for off-label use.
Indeed, the practice of medicine will more than likely require a practitioner to use drugs off-label to provide the most appropriate treatment of a patient. However, because the use of drugs in an off-label capacity can increase the liability risk for a practitioner should an adverse event or poor outcome ensue, proper documentation of the decision-making process for off-label medication use is essential. 2 In conclusion, clinical decision making should always be guided by the best available evidence and the wellbeing of the individual patient. The purpose of off-label use is to benefit the individual patient. Clinicians use their professional knowledge and judgment to determine these uses. In such situations, a clinician may play a significant role in adding to therapeutic information by publishing his or her experience with off-label uses of drugs. These reports can serve as the basis of more formal efficacy and safety studies and can serve as a therapeutic decision-making resource for other physicians. We believe that with proper physician monitoring and patient involvement in shared decision making, off-label prescribing can be effective and safe for individuals. One should always remember evidence-based health care must combine best evidence with physician expertise and individual patient need.
